...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian journal of hospital pharmacy. >Pediatric Assessment of Vancomycin Empiric Dosing 2 (PAVED2): Pharmacotherapy Best Practices Award, sponsored by Sandoz Canada Inc.
【24h】

Pediatric Assessment of Vancomycin Empiric Dosing 2 (PAVED2): Pharmacotherapy Best Practices Award, sponsored by Sandoz Canada Inc.

机译：女性霉素经验液给药2（铺设2）：PharmacToherapy最佳实践奖，由Sandoz Canada Inc.赞助

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Our previous study (PAVED) demonstrated therapeutic vancomycin serum concentrations were not achieved using a common empiric dosing regimen. The purpose of this study was to validate the PAVED dosing regimen by retrospectively applying it to a group of patients who received vancomycin, and evaluating whether this regimen more reliably achieved target serum concentrations than the current regimen. Our objectives were to: i) describe the proportion of patients who would have reached initial target trough concentrations using the PAVED regimen, it) to describe the characteristics pertaining to dosing and pharmacokinetic parameters, iii) to evaluate the concordance between trough concentrations and area under the curve (AUC). Description of the Methods: Following ethics approval, 200 patients aged 1 month—18 years who received vancomycin and had at least two pharmacokinetically interpretable serum concentrations were included. Results: Using British Columbia Children Hospital's (BCCH) current empiric regimen, 110 (55%) individuals obtained initial vancomycin serum trough concentrations <10 mg/L, 58 (29%) achieved between 10-15 mg/L, 27 (14%) between 15-20 mg/L, and 5 (2%) >20 mg/L. Using the regimen recommended by PAVED, a greater proportion of individuals were predicted to achieve target trough concentrations: 65 individuals (32%) <10 mg/L, 71 (36%) between 10-15 mg/L, 35 (18%) between 15-20 mg/L, and 29 (14%) >20 mg/L. 99% of individuals who achieved a trough concentration >10 mg/L also achieved a therapeutic AUC > 400 mg*day/L. Of the individuals who achieved trough concentrations <10 mg/L, 33 (27%) achieved an AUC >400 mg*day/L and 89 (73%) achieved an AUC <400 mg*day/L. Discussion: BCCH's current empiric regimen achieves subtherapeutic trough concentrations in the majority of patients. Conclusions: Although a greater proportion of patients are predicted to achieve therapeutic concentrations with the PAVED regimen, it is also predicted to result in a significant number of patients who will achieve supratherapeutic concentrations >20 mg/L.
机译：简介：我们以前的研究（铺设）显示治疗万古霉素血清浓度，使用常见的经验剂给药方案没有实现。本研究的目的是通过回顾性地将铺设的给药方案验证到接受万古霉素的一组患者，并评估该方案是否比目前的方案更可靠地实现靶血清浓度。我们的目标是：i）描述使用铺设的方案达到初始目标槽浓度的患者的比例来描述与给药和药代动力学参数，iii相关的特性来评估槽浓度和区域之间的一致性曲线（AUC）。对方法的描述：遵循伦理批准，200名18岁的患者接受过万古霉素，并包括至少两种药代动力学上可解释的血清浓度。结果：使用不列颠哥伦比亚省儿童医院（BCCH）电流经验方案，110（55％）个体获得的初始万古霉素血清谷浓度<10mg / L，58（29％）在10-15 mg / L，27（14％）之间）15-20mg / L和5（2％）> 20mg / L.使用铺设推荐的方案，预计更大比例的个体达到目标槽浓度：65个体（32％）<10 mg / L，71（36％）在10-15 mg / L，35（18％）之间在15-20mg / L和29（14％）> 20mg / L之间。达到谷槽浓度的99％的个体也实现了治疗AUC> 400mg * Day / L.达到谷槽浓度<10mg / L，33（27％）的个体达到AUC> 400mg * Day / L和89（73％）达到AUC <400 mg * Day / L.讨论：BCCH目前的经验方案实现了大多数患者的子治疗槽浓度。结论：虽然预计患者比例更大的患者与铺砌的方案达到治疗浓度，但也预计将导致大量患者，该患者将达到SupratTerapeutic浓度> 20mg / L.

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号